A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B

Fattovich, Giovanna; Giustina, G.; Alberti, Alfredo; Guido, Maria; Pontisso, Patrizia; Favarato, S.; Benvegnù, Luisa; Ruol, A

doi:10.1016/s0168-8278(05)80314-9

Cited by 13 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thymus-derived products: Crude thymus extracts (Thymic Fractions 1402 A and Immunoplex 402A, Biotherapeutics, Wisconsin), thymosin fraction 5 and thymosin alpha-1 (Zadaxin, SciClone, California) are cytokines derived from immunologically active proteins found in the thymus gland. Notably, these thymus-derived proteins appear to modulate the progression and stabilization of chronic viral hepatitis (5)(6)(7)(8)(9)(10)(11)(12).…”

Section: Other Therapeutic Cytokinesmentioning

confidence: 99%

Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection

Gish

1999

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects over 170 million people worldwide. While interferon is currently the most used single agent therapy, this drug may result in a sustained loss of virus from the blood in only up to 15% of patients; new options for treatment are needed. With the release of ribavirin in North America and Europe, a viral clearance rate or 'cure' may be attained in up to 40% of patients. Developing successful antiviral therapy that prevents or delays the development of cirrhosis, liver failure and liver cancer as well as decreasing the demand for liver transplantation are clearly identified goals. Unfortunately, there is no complete in vitro model of HCV replication or translation. Due to the lack of an animal or cell culture model of HCV infection, in vitro translation screening systems to identify inhibitors of HCV protein translation are being evaluated by a large number of biotechnology companies. With advancing computer technology, high throughput screening processes are now possible and can be joined to specific in vitro model testing systems. Along with examining some of the information known about HCV therapy and the HCV genome, the present review discusses potential targets for new therapies and identifies therapeutic agents that are nearing clinical application.

show abstract

Section: Other Therapeutic Cytokinesmentioning

confidence: 99%

Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection

Gish

1999

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Interleukin-2 and interleukin-12 are further approaches (Carreno & Quiroga, 1997). Thymic peptides have also been tried in patients with chronic hepatitis B (Fattovich et al, 1994). It is hoped that a greater understanding of the immune mechanisms involved in spontaneous viral clearance will help to design more effective approaches with cytokines.…”

Section: Future Treatmentsmentioning

confidence: 99%

Treatment of Chronic Viral Hepatitis

Main

McCarron

1998

Antivir Chem Chemother

View full text Add to dashboard Cite

Interferon-α therapy has proved effective for up to 40% of patients with adult-acquired chronic hepatitis B virus (HBV) infection and for 20-25% of those with chronic hepatitis C virus (HCV) infection. Nucleoside analogues, such as lamivudine and famciclovir, are showing promise as antiviral agents for chronic HBV and the combination of interferon-α and ribavirin is proving to be successful therapy for 40-50% of patients with chronic HCV. In this article we review current therapy and discuss future strategies of the therapy of chronic viral hepatitis.

show abstract

Hepatitis B and D

Lok

Negro

2011

Schiff's Diseases of the Liver

View full text Add to dashboard Cite

A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B

Cited by 13 publications

References 21 publications

Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection

Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection

Treatment of Chronic Viral Hepatitis

Hepatitis B and D

Contact Info

Product

Resources

About